Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 52M | 28M | 5M | 6M | 38M |
| Gross Profit | 49M | 28M | 5M | 6M | 38M |
| Operating Income | 11M | -40M | -42M | -17M | 18M |
| EBITDA | 14M | -5M | -23M | -17M | 18M |
| Net Income | 32M | -14M | -41M | -17M | 16M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$25.44
+0.09% today
1Y Change
-0.93%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
XOMA Corporation (XOMAP) is a Healthcare stock with a market cap of $500.00M and listed on NASDAQ. The stock last traded around $25.44 and down 0.9% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +83.1%, EPS growth of +192.7%, a dividend yield of 0.0%. What stands out right now is revenue +83.1%, EPS +192.7%, free cash flow +120.9% with operating margin 21.8% and ROIC 4.5%. Valuation already assumes a fairly strong business story at P/E 25.2 and price/sales 9.5. Stock Foundry combines XOMAP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XOMAP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XOMAP Max Drawdown
-7.45%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XOMAP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$38.2M
+533.2% YoY
FY Net Income
$15.8M
+192.4% YoY
Free Cash Flow
-$3.8M
+86.4% YoY
Revenue Growth
+83.1%
EPS Growth
+192.7%
Gross Margin
94.3%
Net Margin
56.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 52M | 28M | 5M | 6M | 38M |
| Gross Profit | 49M | 28M | 5M | 6M | 38M |
| Operating Income | 11M | -40M | -42M | -17M | 18M |
| EBITDA | 14M | -5M | -23M | -17M | 18M |
| Net Income | 32M | -14M | -41M | -17M | 16M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83M | 102M | 153M | 58M | 93M |
| Total Assets | 273M | 221M | 234M | 140M | 167M |
| Total Liabilities | 169M | 139M | 146M | 16M | 25M |
| Shareholder Equity | 104M | 82M | 89M | 124M | 142M |
| Total Debt | 132M | 119M | 124M | 34K | 229K |
| Net Debt | 49M | 18M | -29M | -58M | -93M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
23M
+276.1% YoY
Capital Expenditures
27M
-73.8% YoY
Free Cash Flow
4M
+86.4% YoY
Key ratios
Gross Margin
94.3%
Operating Margin
21.8%
Net Margin
56.4%
ROE
30.2%
Debt / Equity
1.27x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.